FDA Approval for GORE® VIABAHN® VBX Balloon Stent Enhances Aortic Repair Techniques

In a significant advancement for cardiovascular health, the U.S. Food and Drug Administration (FDA) has approved the expanded use of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, known as the VBX Stent Graft. This approval allows for its application in femoral fenestrated endovascular aortic repair (FEVAR) and branched endovascular aortic repair (BEVAR). With this model, vascular surgeons can now utilize a reliable, on-label bridging stent graft specifically tailored for treating complex aortic aneurysms.

Jason Belzer, the Business Leader for Gore Americas, highlighted the importance of this approval, noting that it marks a milestone for physicians who manage complex aortic patients. He expressed pride in offering this crucial tool and underlined Gore's commitment to innovation in advancing treatment options for those suffering from complex aortic diseases.

This pivotal development follows the recent release of promising three-year clinical outcomes from the EMBRACE Registry—a registry designed to assess the real-world usage of the VBX Stent Graft among patients with intricate aortic aneurysms. At the European Society for Vascular Surgery's recent annual meeting, these outcomes were shared, demonstrating robust performance across clinical settings.

The EMBRACE Registry comprised numerous evaluations of patient outcomes using the VBX Stent Graft as a bridging option in FEVAR and BEVAR procedures. The results were encouraging, indicating a vessel-level primary patency rate of 97.5% in a cohort of 103 patients, while freedom from target vessel instability was recorded at 93.9%. For BEVAR, patient data revealed a 94.0% primary patency and 88.4% freedom from instability in encompassed 165 patients.

Dr. Gustavo Oderich, a prominent figure in vascular surgery and educator at Baylor College of Medicine, emphasized how FEVAR and BEVAR have reshaped the treatment landscape for complex aortic aneurysms through innovative, minimally invasive approaches. As these methods evolve, standardizing evidence-based practices in bridging stent use becomes vital. The FDA approval of the VBX Stent Graft, complemented by a body of clinical evidence, represents an essential leap forward, fostering better outcomes for patients undergoing these intricate procedures.

Additionally, U.S. vascular surgeons have voiced consistent interest in improving clinical data, focusing on areas such as reintervention rates and long-term durability of these stent grafts. The flexibility of the VBX Stent Graft, designed with balloon-expandable technology, allows for precise deployments tailored to specific procedural needs.

This advancement follows the CE Mark indication received in Europe in 2025, which permitted the stent graft's on-label use in similar aortic repairs. Since the initial U.S. launch, more than 600,000 units have been utilized globally, underscoring the demand for advanced vascular solutions.

Gore’s tools are part of a broader mission to revolutionize the treatment of cardiovascular conditions and other health issues. With an impressive history of over 55 million medical device implants in the last 50 years, Gore is committed to enhancing patient outcomes via quality innovations and clinical education, aiming for sustainable healthcare solutions that benefit physicians, hospitals, and insurers alike.

For more detailed information regarding the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, including comprehensive usage guidelines, it is recommended to refer to Gore’s official medical website.

This FDA approval represents not just a triumph in medical technology but a brighter future for patients facing complex vascular challenges, allowing for less invasive, more effective treatment methodologies.